First-line Keytruda Doubles 5-Year Survival in Certain Lung Cancer Patients, Data Show
News
First-line treatment with Keytruda (pembrolizumab) continues to promote significant survival benefits and durable responses in people with metastatic non-small cell lung cancer (NSCLC) and high levels of PD-L1, compared with standard chemotherapy, ... Read more